On September 10th, Beton Biotech announced a strategic partnership with Microgene (Suzhou) Co., Ltd. (referred to as "Microgene") to conduct in-depth cooperation in gene editing systems, gene editing fusion proteins (CAS12 proteins), and non-integrating viral particle (VLP) delivery systems, and to jointly promote the development and commercialization of gene editing therapy. This strategic partnership will further expand Beton Biotech's technical platform capabilities, leveraging Microgene's powerful gene editing tools and VLP delivery system to expand the application of gene editing technology in cell and gene therapy, from platform innovation to project delivery, from CRO to CDMO.